Podcasts about principle investigator

Today's episode is going to focus on the workup of a patient with a suspected multiligamentous knee injury as well as a surgical approach that follows – including acute versus delayed surgery, repair versus reconstruction, surgical technique and order of operations in the OR. We are joined today by two outstanding guests! Dr. Matt Provencher is an orthopedic surgeon at the Steadman Clinic in Vail Colorado, Principle Investigator at the Steadman Philippon Research Institute and assistant Editor-in-Chief of Arthroscopy.  He is very active in academic societies and serves on the Board of Directors for AOSSM, AANA and SOMOS.Dr. Armando Vidal is also an orthopedic surgeon at the Steadman Clinic in Vail and is the Vice President of the Medical Staff of Vail Health Hospital.  He is was previously the head team physician for the Denver Nuggets, and  former team physician for the University of Colorado men's basketball and the University of Denver men's hockey.So, without further ado, let's get to the Field House!

This year's AD/PD Conference was held in Vienna, Austria from the 1st to 5th April. In this first of a two-part special we bring you highlights from the first three days of the conference. The AD/PD Conference focuses on basic science and translational and clinical research bringing New insights on disease mechanisms and etiologies, the latest findings from clinical trials, innovative outlooks on therapy and prevention and advances in diagnostic markers. In this special on-location recording our guest host Dr Amanda Heslegrave, Principle Investigator and Co-Lead of fluid biomarker laboratory from the UK Dementia Research Institute at University College London talks with: Dr Loukia Katsouri, Senior Research Fellow at the UCL Gatsby Foundation. Loukia studies the molecular mechanisms of tau propagation in Alzheimer's disease. She aims to understand how the presence of tau is affecting the spread and the severity of the disease. Dr Anna Mallach, Research Fellow in the UK Dementia Research Institute at Imperial College London. Anna's work focusses on understanding the role of cellular interactions in contributing to neurodegenerative diseases. Dr Imogen Swift, Research Scientist at Vesper Bio. Imogen is a neuroscience specialist focusing on biomarker and preclinical development in neurodegenerative therapeutics spanning frontotemporal dementia, Alzheimer's Disease. Here are just a few highlights from the discussion:

Matters Microbial #84: Detecting Pathogens — and Worse — in Wastewater March 27, 2025 Today, Dr. Rachel Poretsky, Associate Professor of Biological Sciences at the University of Illinois Chicago joins the #QualityQuorum to discuss how examining wastewater (and related water) can give insights into the presence of pathogen antimicrobial resistance genes and even microbial ecology. Host: Mark O. Martin Guest: Rachel Poretsky Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A link to demonstrate the wonders of the Marine Biological Laboratories' Microbial Diversity course, which I know for a fact is life changing. Recommended by David Ranada, an article about water bottles and microbes.   An essay about the Chicago River and cholera, which led to the necessity of effective waste water treatment. An overview of the complexities of waste water treatment.  Here is a video on that topic.   An essay by Carl Zimmer about the microbial ecology of lakes…and human beings. How “recreational water quality” is determined. An article describing the microbiota associated with human biological waste with an amusing name (scroll down). How qPCR can be used to determine the prevalence of specific microbes. A recent article from Dr. Poretsky's research group, investigating how antimicrobial resistance genes can move through a hospital waste water system. A link to the Bacterial-Viral Bioinformatics Resource Center, for which Dr. Poretsky is a Principle Investigator. The Illinois state wastewater surveillance dashboard.  Fascinating! A Discovery Channel documentary on virus hunting and surveillance that includes Dr. Poretsky. Dr. Poretsky's faculty webpage. Dr. Poretsky's webpage for her research group. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

3500 TEENS ・ 2 RESEARCHERS ・ 1 QUESTION What are adults missing about teens and technology? A lot. Harvard University Project Zero researchers, Common Sense Media collaborators, and real-life parents Emily Weinstein and Carrie James are the authors of BEHIND THEIR SCREENS: What Teens are Facing (and Adults are Missing). In their book, James and Weinstein combine their years of research on technology use by adolescents—including data gathered during the first year of the COVID pandemic—to explore how teens use their phones, messaging apps, social media, and more to navigate their real-world relationships in new and surprising ways. The authors also have the benefit of the expertise of teens themselves. By working with dozens of middle and high school students across the United States—part of the authors' Teen Advisory Council—Weinstein and James explain in adolescents' own words why they do what they do online, and what tweens and teens wish their parents understood about the connected world they're living in. Emily Weinstein is a Research Director at Project Zero at Harvard and a Lecturer at the Graduate School of Education. Carrie James is a sociologist and Principle Investigator at Project Zero at the Harvard Graduate School of Education. She is the author of Disconnected: Youth, New Media, and the Ethics Gap (MIT Press). The authors' work has been covered in Time, the Boston Globe, the Washington Post, and the Atlantic, and they are sought-after speakers on teens and technology. You can learn more at www.behindtheirscreens.com         Learn more about your ad choices. Visit megaphone.fm/adchoices

Lethbridge Polytechnics's Centre for Public Safety Applied Research (CPSAR) has been embracing Klose's (2024) re-definition of evidence-based policing approach that entails decision-making, “which integrates the best available evidence, professional judgement and community values, preferences and circumstances”. CPSAR currently supports over 14 different research projects, 15 researchers, 14 student researchers that involve meaningful collaborations with over 28 Canadian policing, public safety, academic, and community partners across five provinces. We hope to share the benefits and potential of using “research-informed, practitioner-centred, and community-oriented” (Klose, 2024) evidence-based policing practices overall. We will share the research questions, objectives, methods, and initial data collected and analyzed for a 3-year project based in Lethbridge, which is currently SSHRC/NSERC funded (Community Integration Through Art – Pissatsinaskssini), that has emerged from this redefinition of evidence-based approaches in public safety in Canada. Findings regarding policing, community, and academic partnerships will be shared including current trends, challenges, and opportunities shared by police services. These findings have served to inform current research projects, collaborations, and grant applications. Key findings from our CITAP project, which aims to reduce recidivism and facilitate reconciliation, will be shared about our priority population, including their self-reported preferences and input from service providers on the social-recreational gatherings we are implementing. Practically, we aim to show how co-created, multi-disciplinary, research-informed applied research projects that reflect community values and circumstances can result in meaningful societal benefits. Speakers: Dr. Kirsten Fantazir, President's Applied Research Chair in Public Safety and Dr. Jami Albright-Tolman, Principle Investigator, Researcher and Faculty, Lethbridge Polytechnic Dr. Kirsten Fantazir is an experienced instructor, curriculum developer, researcher, chair, graduate supervisor and mentor at Lethbridge Polytechnic. Kirsten is currently researching the re-integration of marginalized populations through art, technology-facilitated gender-based violence in youth, and authentically assessing police applicants through virtual reality. In 2022, she was named the first President's Applied Research Chair in Public Safety. Kirsten has since led the Centre for Public Safety Applied Research (CPSAR) which is supported by faculty researchers and student research assistants who currently oversee numerous applied research projects with public safety, community, technology, and academic partners. Dr. Albright-Tolman is an instructor and researcher at Lethbridge Polytechnic in Lethbridge, Alberta. Her research focuses on enhancing public safety by improving social determinants of health in marginalized populations. Currently, she is researching the re-integration of marginalized populations through art and addressing technology-facilitated gender-based violence in youth. She has also designed, implemented, and evaluated an online gambling harm reduction program for offenders called Hedge Your Bets.

In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks with Dr. Andrew Allard about Palindromic Arthritis. Andrew explains what Palindromic Arthritis is and when the term used. He talks about symptoms, treatments and a longer term outlook for people who have may have received this diagnosis.  Dr Allard is a Consultant Rheumatologist at the Royal National Hospital for Rheumatic Diseases, RUH Bath, the Lead Consultant for the Rheumatoid Arthritis service and Principle Investigator on Clinical Trials and Studies related to Rheumatoid Arthritis. He also runs subspecialty clinics in Early Inflammatory Arthritis and Psoriatic Arthritis, a weekly musculoskeletal ultrasound list and has an interest in immunotherapy-induced rheumatic disease.    Useful Links: Versus Arthritis Bath Institute for Rheumatic Diseases Podcasts  Connect with Us: Have questions or thoughts about our information Podcast library?  Interested in joining BIRDs patient research panel?  Email Mel at  ppe@birdbath.org.uk Be sure to subscribe, rate, and review the podcast to help us continue sharing information that matters! The Patient and Public Engagement Programme is supported by hands-off sponsorships from Eli Lilly and Company Limited, UCB and Amgen -all of whom have provided grant funding but who have were not involved in the development, content or editorial control of this podcast, nor the subsequent review and approval of these materials or general running of the patient and public engagement programme. We would also like to thank The Arnold Clark Community Fund, The Cumber Family Charitable Trust, Medlock Charitable Trust, The Ray Harris Charitable Trust and The Hospital Saturday Fund. Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases. Please visit the⁠ ⁠⁠⁠⁠⁠⁠⁠BIRD website ⁠⁠⁠⁠⁠⁠⁠⁠ to sign up for news.

This week we discuss the increasing strain on scientific publishing with Mark Hanson, a Principle Investigator from the University of Exeter, UK. The number of scientific publications are rising at an alarming rate and disproportionately to the number of scientists. We talk about why this is happening and what some of the solutions might be. Read the full paper -> https://direct.mit.edu/qss/article/5/4/823/124269/The-strain-on-scientific-publishing  Explore the data yourself -> https://the-strain-on-scientific-publishing.github.io/website/  Mark's lab -> https://mahansonresearch.weebly.com/  Find Mark on Bluesky -> https://bsky.app/profile/hansonmark.bsky.social  Blog post mentioned by Mark -> https://mahansonresearch.weebly.com/blog/we-need-a-new-special-issue-lexicon This episode was produced by Jonny Coates and edited by Sonia Gomes Pereira. Music by Dr John D Howard. Submit your question that you'd like us to answer directly (https://www.speakpipe.com/preprints) or contact us via our website.  If you enjoyed this show then hit that subscribe button and leave a review (on Apple Podcasts or Spotify). If you love what we are trying to do then buy us a coffee https://www.buymeacoffee.com/preprints! Any contribution is greatly appreciated. For the latest podcast news and updates follow us on Instagram @Motion_Pod or visit our website; www.preprintsinmotion.wordpress.com. Preprints in Motion is a Rippling Ideas production. Find us on social media: Jonny @JACoates.bsky.Social, Camila (@Kamo_Valenzuela) & Sonia (www.linkedin.com/in/soniagomespereira). 

This week we are re-releasing a classic episode from the Go Help Yourself archives! In this episode, originally released in 2019, we review the #1 Amazon bestseller: Attached. The New Science of Adult Attachment and How It Can Help You Find—and Keep—Love by Amir Levine, M.D., and Rachel S.F. Heller, M.A. Dr. Amir Levine, M.D., is an adult, child, and adolescent psychiatrist and neuroscientist. He graduated from the residency program at the New York Presbyterian Hospital/Columbia University, where he is currently a Principle Investigator, together with Nobel Prize Laureate Dr. Eric Kandel and distinguished researcher Dr. Denise Kandel, on a National Institute of Health sponsored research project. He also has a private practice in Manhattan.Rachel S. F. Heller, M.A., holds a master's degree in social-organizational psychology from Columbia University. She has worked in the past as a corporate consultant for several management consulting firms, including PriceWaterhouseCoopers, KPMG Consulting and Towers Perrin, where she managed high profile clients. She lives with her husband and three children in the San Francisco Bay Area.We cover all three attachment styles in this Attached book review, including:-Anxious -Avoidant -SecureIf you want more information, you can check out the authors' website here. If you like what you're hearing, you can purchase the book here.And don't forget to subscribe, rate, and review Go Help Yourself!Advertising Inquiries: https://redcircle.com/brands

As part of Science Week 2024 Maynooth University will be hosting an event tomorrow evening called “Ozempic – unravelling fact from fiction”. Dr Andrew Hogan, Senior Lecturer at the Department of Biology at Maynooth University and Principle Investigator with the Obesity Immunology Research Group.

Dr. Sabina Brennan is a neuroscientist, chartered health psychologist, and bestselling author. Known for her ability to translate complex neuroscience into practical advice, Sabina empowers people to take control of their brain health and manifest their goals more effectively. Her latest book, *The Neuroscience of Manifesting*, offers a scientific framework for understanding manifestation and its real-world applications, grounded in cutting-edge brain research. Expect to learn: — What manifestation really is and the myths that need debunking. — How neuroscience can explain the power of manifestation. — The psychological processes and brain areas involved in effective manifesting. — Why self-compassion is such a vital component of the process. And more. You can learn more about Sabina's work at https://superbrain.ie. --- Sabina Brennan is currently an Adjunct Assistant Professor at the ADAPT Centre in Trinity College Dublin where she is a principal investigator in E-Health. Prior to this she was a research assistant professor at the School of Psychology and a principal investigator at the Institute of Neuroscience. She was co-director of the NEIL Research Programme and director of the NEIL Memory Research Unit which profiles cognitive function in a cohort of ~1000 Irish adults aged 50 and over. Understanding differential decline in cognitive ageing and dementia, cognitive reserve, brain health, modifiable risk and protective factors and the development of interventions to prevent or delay the onset of decline, She was a member of the applicant team that secured the biggest philanthropic grant (138 million) in Irish history She coordinated ASAPS, an FP7 Project under the 2012-HEALTH-2012 which promoted brain health and brain research outputs of this project include a website (www.hellobrain.eu) a series of films and a brain health app She is principal Investigator on a US funded 2-year project aimed at assessing the Impact of relationship-based mealtime intervention on quality of life, cognitive function, social connection, mood, BMI, and walking speed. She is also a principle investigator on a 3-year cohort study, DeStress looking at Cognitive function, caregiver stress and cortisol: Mechanisms and implications for prevention of adverse health consequences in spouse dementia caregivers. funded by the Medical Research Charities Group and the Health Research Board. She is Principle Investigator on a project that developed a series of 10 films (www.freedliving.com) aimed at addressing fears about memory loss and dementia. She has co-supervisor PhD students investigating Protective Effect of Cognitive Reserve against Cognitive Impairment (IRCHSS), a second PhD, looking at the relationship between caregiver stress and frailty and indices of cognitive decline, (IRC Enterprise Partnership scheme and third investigating the relationship between age-related hearing loss and cognitive decline. Her own PhD thesis entitled 'Neurocognitive and Electrophysiological Indices of Cognitive Performance in Ageing' explored individual differences in cognitive performance in healthy elderly and aimed to identify neurocognitive and electrophysiological markers that index cognitive decline. As part of the TCIN-GSK Neurodegeneration Programme she was responsible for a research project aimed at identifying novel cognitive, electrophysiological and behavioural endpoints in human participants that offer greater sensitivity to age-induced cognitive changes than previous endpoints. --- Interview Links: — Sabina's website - https://superbrain.ie.

This continuing education activity is provided by AffinityCE and CheckRare CE. This activity provides continuing education credit for physicians. A statement of participation is available for other attendees. Estimated time to complete: 0.50 hoursTo obtain CME credit, go to https://checkrare.com/learning/p-cushings-syndrome-treatment-research-highlights-endo-2024/Commercial SupportEducational Support for this activity was provided by Recordati Rare Diseases, Inc., and Xeris Pharmaceuticals.Learning ObjectiveAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with Cushing's syndrome and its clinical relevance.Share new information with their clinical team. Activity DescriptionThis 30-minute CME program highlights the latest clinical research about Cushing's syndrome and Cushing' disease.Cushing's syndrome is rare endocrine disorder characterized by chronic hypercortisolism. It is often due to a pituitary adenoma producing excessive ACTH leading to hypercortisolism. Symptoms can range from mild to extensive.This CME program, hosted by Maria Fleseriu, MD, FACE, Professor of Medicine and Neurological Surgery, Director of the Pituitary Center at Oregon Health & Science University, provides an overview of the latest clinical research presented at ENDO 20234 involving Cushing's syndrome. FacultyMaria Fleseriu, MD, FACEProfessor of Medicine and Neurological SurgeryDirector of Pituitary CenterOregon Health & Science UniversityPortland, OregonDisclosure StatementAffinityCE and CheckRare CE staff, as well as planning and review committees, have no financial interests to disclose. Faculty EducatorsDr. Fleseriu discloses the following relevant financial relationships with ineligible companies to disclose:Funding to the University as Principle Investigator from Sparrow PharmaceuticalsScientific consultant for Crinetics Pharmaceuticals, Recordati Rare Diseases, Sparrow Pharmaceuticals, and Xeris PharmaceuticalsMitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre- and post-program assessments. Your certificate will be emailed to you in within 30 days.Participation CostsThere is no cost to participate in this CME session. To receive CME credit for your participation, please complete the pre- and post-program assessments. Your certificate will be emailed to you in within 30 days.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.com.Send customer support requests to cds_support+ldrtc@affinityced.com.Copyright© 2024. This CME-certified activity is held as copyrighted © by AffinityCE and CheckRare CE. Through this notice, AffinityCE and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Did you know that the way your skin ages may indicate the presence of neurodegenerative diseases, such as Alzheimer or Parkinson's diseases, lung aging and cardiovascular diseases? This and much more in an extremely interesting episode presented by Prof. Jan Gutermuth,  Chair and Principle Investigator of the Department of Dermatology at Universitair Ziekenhuis Brussel and Dr. Eugenia Makrantonaki, researcher in several Universities in Germany, with more than 25 year-experience in skin aging. The conversation covers the role of hormones and genes in both women and men, indicating that the skin ages in the same way for both genders. Also, Dr. Makrantonaki explaines the term ‘Inflammaging', used to identify a low grade inflammation in our skin and reminds how lifestyle and stress can deeply influence the way our skin ages.   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/

Today's episode is going to focus on the workup of a patient with a suspected multiligamentous knee injury as well as a surgical approach that follows – including acute versus delayed surgery, repair versus reconstruction, surgical technique and order of operations in the OR. We are joined today by two outstanding guests! Dr. Matt Provencher is an orthopedic surgeon at the Steadman Clinic in Vail Colorado, Principle Investigator at the Steadman Philippon Research Institute and assistant Editor-in-Chief of Arthroscopy.  He is very active in academic societies and serves on the Board of Directors for AOSSM, AANA and SOMOS.Dr. Armando Vidal is also an orthopedic surgeon at the Steadman Clinic in Vail and is the Vice President of the Medical Staff of Vail Health Hospital.  He is was previously the head team physician for the Denver Nuggets, and  former team physician for the University of Colorado men's basketball and the University of Denver men's hockey.So, without further ado, let's get to the Field House!

Dr. Amy Mainzer is a Senior Research Scientist and the Principle Investigator for the Near Earth Object Wide-field Infrared Survey Explorer (NEOWISE) mission at the NASA Jet Propulsion Laboratory. She is also the Principal Investigator for the Near Earth Object Camera mission proposal and the Deputy Project Scientist for the Wide-field Infrared Survey Explorer mission. Amy is an infrared astronomer. She studies the universe using wavelengths of light that are longer than those we can see. Infrared astronomy is especially useful for looking at objects that are relatively cool in temperature such as asteroids. When she's not at work, you can find Amy hanging out with friends at the local roller disco. For her, it's a great way to get some exercise, and it's fun to do something completely different from her work at NASA. After earning her B.S. In Physics from Stanford University, Amy accepted a position at the Lockheed Martin Advanced Technology Center. She then returned to academia to earn her M.S. in Astronomy from the California Institute of Technology and PhD in Astronomy from the University of California, Los Angeles. Amy has received many awards and honors for her work, including the Lew Allen Award for Excellence, as well as the NASA Exceptional Achievement and Scientific Achievement Medals. She has also been recognized along with NASA team members for their efforts on the Spitzer, WISE, and NEOWISE missions. In this interview, Amy discusses her life and science.

Asian elephants are the largest land mammals on the Asian continent and play a crucial role as keystone species and ecosystem engineers. Distinguished by their smaller ears and domed heads compared to their African counterparts, these gentle giants once roamed across diverse habitats from grasslands to rainforests throughout Asia. However, their population has sharply declined due to habitat loss, fragmentation, and human-elephant conflicts. It's conjunction with World Elephant Day, celebrated annually on the 12th of August, we want to discuss why ensuring their survival is crucial to both people and planet, with Associate Professor Dr Wong Ee Phin, an elephant ecologist and the Principle Investigator from the Management and Ecology of Malaysian Elephants or MEME, which is a research organisation working on developing evidence-based approach to the conservation of Asian elephants in Peninsular Malaysia. Image Credit: ShutterstockSee omnystudio.com/listener for privacy information.

Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier and significantly improve lung cancer mortality. Yet they remain underutilized and are only being used to detect certain types of lung cancer, specifically, smoking-related lung cancer. Guest: Dr. Pan-Chyr Yang is a Professor and former President of National Taiwan University College of Medicine and recipient of the IASLC Joseph W. Cullen Prevention & Early Detection Award at the 2020 WCLC. Guest: Dr. Elaine Shum is an Assistant Professor of Medicine at New York University Grossman School of Medicine and Principle Investigator of the Female Asian Nonsmoker Screening Study (FANSS), for which she received the Distinguished Young Investigator Research Award from the EGFR Resisters Summit.

In this episode of Causes or Cures, Dr. Eeks chats with Dr. Randall Urban about his research on the link between Long COVID and growth hormone and how growth hormone may potentially reverse or decrease the neurological symptoms/brain fog associated with Long COVID. Dr. Urban is an endocrinologist at the University of Texas Medical Branch (UTMB) in Galveston, Texas. He is the Vice Dean of Clinical Research in the School of Medicine, Vice President and Chief Research Officer, and the Principle Investigator of UTMB's Clinical Translational Science Award. You can learn more about his research here. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here.Support the Show.

In this episode of the MGC podcast, I talk to Dr. Rhonda Voskuhl, a Professor of Neurology at UCLA where she currently holds the Jack H. Skirball Chair. Dr. Voskuhl is the Director of the UCLA Multiple Sclerosis Program, and is the faculty neurologist for the UCLA Comprehensive Menopause Care Program. She is an internationally recognized expert on women's health and the role of female sex hormones in cognitive decline and neurodegenerative disorders. With over 20 years of numerous grants and continuous funding from the NIH and NMSS, her lab discovered a novel estrogen treatment strategy that can be neuroprotective through actions on estrogen receptor beta (ER) in the central nervous system. Dr. Voskuhl has been the Principle Investigator on three clinical trials showing neuroprotective effects of estriol treatment on cognition and cortical brain atrophy underscoring the translational nature of her research. In this podcast, I talk to her about the following topics: • The role of estrogen on specific receptors in the brain and its implications for the development of neurodegenerative disorders • Why women are more likely to develop early cognitive decline and Alzheimer's disease • Why the earlier clinical trials with estrogen receptor replacement failed • What women can do to slow cognitive decline after menopause

In this episode of the MGC podcast, I talk to Dr. Rhonda Voskuhl, a Professor of Neurology at UCLA where she currently holds the Jack H. Skirball Chair. Dr. Voskuhl is the Director of the UCLA Multiple Sclerosis Program, and is the faculty neurologist for the UCLA Comprehensive Menopause Care Program. She is an internationally recognized expert on women's health and the role of female sex hormones in cognitive decline and neurodegenerative disorders. With over 20 years of numerous grants and continuous funding from the NIH and NMSS, her lab discovered a novel estrogen treatment strategy that can be neuroprotective through actions on estrogen receptor beta (ER) in the central nervous system. Dr. Voskuhl has been the Principle Investigator on three clinical trials showing neuroprotective effects of estriol treatment on cognition and cortical brain atrophy underscoring the translational nature of her research. In this podcast, I talk to her about the following topics: • The role of estrogen on specific receptors in the brain and its implications for the development of neurodegenerative disorders • Why women are more likely to develop early cognitive decline and Alzheimer's disease • Why the earlier clinical trials with estrogen receptor replacement failed • What women can do to slow cognitive decline after menopause

KMOX's Stuart McMillian got a preview of SLU's water summit when he spoke with Dr. Jason Knouft, Principle Investigator for the WATER Institute at SLU.

Francis Halzen is Professor of Physics at the University of Wisconsin–Madison and the Principle Investigator at the Ice Cube Neutrino Observatory

3500 TEENS ・ 2 RESEARCHERS ・ 1 QUESTION What are adults missing about teens and technology? A lot. Drawing on perspectives from more than 3,500 teens, Harvard Project Zero researchers Emily Weinstein and Carrie James bring stories and data together for a powerful reframe of what teens are up against – and what teens need adults to understand. Emily Weinstein is a Research Director at Project Zero at Harvard and a Lecturer at the Graduate School of Education. Carrie James is a sociologist and Principle Investigator at Project Zero at the Harvard Graduate School of Education. She is the author of Disconnected: Youth, New Media, and the Ethics Gap (MIT Press). The authors' work has been covered in Time, the Boston Globe, the Washington Post, and the Atlantic, and they are sought-after speakers on teens and technology. You can learn more at www.behindtheirscreens.com       Learn more about your ad choices. Visit megaphone.fm/adchoices

John Mather is a Senior Astrophysicist in the Observational Cosmology Laboratory at NASA's Goddard Space Flight Center. He was the recipient of the 2006 Nobel Prize in Physics for his role as Principle Investigator for the Far IR Absolute Spectrophotometer on COBE, which observed the cosmic microwave background and helped support the big bang theory of the origin of the universe. John has also worked on many other projects for NASA, including the James Webb Space Telescope. In this episode, Robinson and John discuss the big bang and the cosmic microwave background before detailing the COBE satellite, its extraordinary findings, and the work that led to winning the Nobel Prize. The Very First Light: https://a.co/d/6iaWMOK OUTLINE 00:00 In This Episode… 00:35 Introduction 02:56 John's Scientific Background 12:50 Where Did the Big Bang Theory Come From 22:28 The Electromagnetic Spectrum 27:48 John's Thesis and the Road to COBE 42:57 Designing the Nobel-Winning COBE Satellite 01:05:38 Some Further Background 01:08:08 The Cosmic Microwave Background and the Nobel Prize 01:35:52 John's More Recent Projects Robinson's Website: http://robinsonerhardt.com Robinson Erhardt researches symbolic logic and the foundations of mathematics at Stanford University. Join him in conversations with philosophers, scientists, weightlifters, artists, and everyone in-between.  --- Support this podcast: https://podcasters.spotify.com/pod/show/robinson-erhardt/support

This may be our most fascinating podcast ever! We are joined by the Co-Founder of Rion, Inc., researcher and pioneer of regenerative medicine, and Cardiologist at the Mayo Clinic, Atta Behfar, MD, PhD. We're also joined by Saranya Wyles, MD, PhD, Associate Professor of Dermatology, Program Director of Clinical Regenerative Medicine Education at Mayo Clinic and the Principle Investigator for Rion Aesthetic's flagship product, (plated)™.  Dr. Behfar spent several years in the initial stages of research getting a deep understanding of what influences cells to participate in wound healing. His research led him to find the major gap- communication-  which is where exosomes come into play. They are the mechanism by which cells communicate with one another and make things happen in the body. Next, it was about finding the best communicators which led him and his research team to identify a particular group of platelet-derived exosomes that were specifically communicating about regeneration and repair.  This was a true needle in a haystack endeavor, and thankfully it's paid off-  it's propelled regenerative medicine in aesthetics to a whole new level.  Several years later, his findings turned into Rion, Inc as he continued on with research focused on organ regeneration (eventually the heart), and as a byproduct, he found an invaluable application within aesthetics. Looking into the future, he discusses what is possible with injectable exosomes to supercharge what filler, toxin and biostimulators can do in the tissue.  We won't need to just fill or relax wrinkles, but there is the potential to repair the tissue enough that it's no longer a concern. If Dr. Behfar is where it started, Dr. Wyles is how it's going. Not only is she an expert in regenerative medicine, but she's also a practicing Dermatologist. She is using exosome technology in her practice daily, and to hear her discuss the effectiveness and results she sees with (plated)™ is remarkable. She is using it as a primer for her patients before procedures, as their primary skincare product, and as a post-treatment wound-healing accelerant. While this is not a sponsored Rion Aesthetic's podcast, the results she's seeing clinically, not just in the lab, are cause for major kudos to the Rion Aesthetics research team! She's working on next steps toward future research involving hair growth, injectable exosomes and atopic dermatitis among other potential uses- all pending the FDA of course. She truly is the perfect intersection of where the research lab meets the treatment chair.  We are definitely at the tip of the spear in regenerative medicine with this episode. It's rare to sit down with two of the best and brightest minds on the research front and get a solid breakdown of the science and the clinical application of something as novel as platelet-derived exosomes. In addition, Dr Wyles provides a checklist of sorts for you to consider before bringing exosomes into your practice. It's important to check things like donor quality, batch consistency, batch effectiveness, platelet or stem-cell derived, and to ask for the clinical research that is backing the product. We know Rion Aesthetics has no shortage of research available, and from the sound of what's next, they are only getting started!

In this episode, hosts Joe and Lesley chat with Dr. Ewoud Schmidt about his work in studying neuronal circuit development, function, and behavior and how human-specific genes shape neuronal circuits in health and disease. Dr. Schmidt is an Assistant Professor and the Principle Investigator for the Schmidt Lab at the Medical University of South Carolina. Episode Guest: Ewoud Scmidt @ereschmidt Episode Hosts: Lesley Colgan @colgan_lesley Joe Schumacher @JWscience Max Planck Florida's Neurotransmissions Podcast Website: https://www.mpfi.org/news-media/podcast Social Media: @MPFneuro Twitter: https://twitter.com/MPFNeuro Instagram: https://www.instagram.com/mpfneuro Facebook: https://www.facebook.com/MPFNeuro

The wider community of liver stakeholders witnessed an exciting July as new compelling data and presentations were revealed across two major meetings, EASL Congress and the American Diabetes Association Scientific Sessions. Throughout that month, SurfingNASH provided real-time coverage and review of the emerging stories spanning topics like drug development, new nomenclature, omics and AI, NITs and more. For this episode the trio of co-hosts, Jörn Schattenberg, Louise Campbell and Roger Green, embark on their first exclusive discussion together in a while without any guest panelists. The overarching theme of the program observes what has made 2023 interesting and exciting thus far before offering a look into what the audience can expect to learn more about in the imminent months.This conversation begins with Louise detailing a paper that she recently co-authored on 'The Accuracy of Ultrasound Controlled Attenuation Parameter (CAP) in Diagnosing Hepatic Fat Content.' The aim of this study was to delineate the accuracy of CAP in diagnosing hepatic steatosis, compared to the gold standard of liver biopsy. Notes on the topic broaden to consider the value of elastography and the challenges of making proper use of it. From here, the group shares comments around how the major events and conferences have panned out so far for 2023. Jörn notes that while the volume of information available grows over time, a clear set of events which captures attention relates to the advancement of resmetirom as a potential first approval for NASH-directed therapy. He recounts the trajectory of this story beginning in December 2022 with a press release of positive Phase 3 topline results, to follow up data presented at EASL Congress 2023 in June. Jörn highlights his excitement for analyzing these results on the podcast with Stephen Harrison, Principle Investigator of the MAESTRO studies. Briefly, Jörn underscores the second key event of the year: new nomenclature for liver diseases. When his comments around this conclude, the trio spend the rest of this conversation discussing the importance behind a resmetirom approval and some of the interesting data that emerged from later releases of the MAESTRO trials. Reviewing this episode and the various conversations is a strong reminder of how much information has already become available this year and what it portends in terms of future episodes and an ever-increasing explosion of new information about liver disease, drugs, testing, and so much more. If you have questions or comments around the EASL Congress or ADA meetings, the discussed therapeutics, new nomenclature, or any other topic addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

The wider community of liver stakeholders witnessed an exciting July as new compelling data and presentations were revealed across two major meetings, EASL Congress and the American Diabetes Association Scientific Sessions. Throughout that month, SurfingNASH provided real-time coverage and review of the emerging stories spanning topics like drug development, new nomenclature, omics and AI, NITs and more. For this episode the trio of co-hosts, Jörn Schattenberg, Louise Campbell and Roger Green, embark on their first exclusive discussion together in a while without any guest panelists. The overarching theme of the program observes what has made 2023 interesting and exciting thus far before offering a look into what the audience can expect to learn more about in the imminent months.Louise starts by detailing a paper that she recently co-authored on 'The Accuracy of Ultrasound Controlled Attenuation Parameter (CAP) in Diagnosing Hepatic Fat Content.' The aim of this study was to delineate the accuracy of CAP in diagnosing hepatic steatosis, compared to the gold standard of liver biopsy. From here, Jörn shares his take on the biggest stories of the year thus far. He begins by recounting the December 2022 press release of positive Phase 3 topline results for resmetirom and describes how the data was presented at EASL Congress 2023. Jörn highlights his excitement for analyzing these results on the podcast with Stephen Harrison, Principle Investigator of the MAESTRO studies. Secondly, Jörn underscores the adoption of new nomenclature as an obvious hallmark of the year.Roger notes several developments in the resmetirom story following the EASL presentation, namely around a submission to FDA and potential timeline for approval. Louise suggests that, "from the patient advocacy perspective, there has to be something approved shortly to prove that the path that the FDA has set is actually achievable." The group also explores the importance behind having quality of life measures as opposed to solely targeting histological improvement of fibrosis. These ideas lead Roger to register his interest in developing understanding around the role of inflammation which has been explored more recently on the podcast.The conversation shifts to consider the new nomenclature and what activities are required in its successful implementation. Several important ideas emerge around education and moving forward collectively in continued pursuit of promoting liver health and saving lives. Jörn summarizes that fundamentally the patients and the disease remain the same and that there is actionable knowledge around how to prevent, diagnose and treat. As the session winds down, the trio focus on providing a glimpse into what's coming up for the SurfingNASH program. Listen on to learn more about what you can expect to hear from the Surfers!If you have questions or comments around the EASL Congress or ADA meetings, the discussed therapeutics, new nomenclature, or any other topic addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On 

Throughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy past month at both the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. To reflect on the insight-laden occasion, Stephen Harrison and Jörn Schattenberg join Roger Green to explore emerging drug development stories in detail.This conversation focuses largely on therapeutic candidate, resmetirom, and a series of MAESTRO-NASH trials that will hopefully lead to a first drug approval and treatment for NASH. Stephen, lead Principal Investigator of the MAESTRO program, begins by outlining the resmetirom clinical trial package in its entirety. Before Stephen shares numbers from the trial, Jörn opens a discussion around efficacy endpoints. He notes the structure of reading biopsy and suggests that reporting improvement in fibrosis and NASH resolution might not accurately reflect the extent of efficacy once the MAESTRO outcomes trial completes several years from now and patients are treated in practice. Stephen goes on to share the efficacy outcomes of the MAESTRO-NASH trial and offers notes from several different perspectives around dosing, placebo, metrics and other elements of the study population. Finally, Stephen suggests where in the liver he believes the drug works and why the drug might have more robust effects than can currently be measured using the testing tools available.If you have questions or comments around the EASL Congress or ADA meetings, the discussed therapeutics, new nomenclature, or any other topic addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Throughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy past month at both the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. For this feature, Stephen Harrison and Jörn Schattenberg discuss at depth drug development insights emerging from the meetings with host Roger Green.As lead Principle Investigator, Stephen expounds on Phase 3 MAESTRO-NASH data on resmetirom that he presented during the opening general session. He begins with a cogent backdrop of the study parameters, including endpoint criteria, before detailing results and implications. In his analysis, Stephen notes the challenges of teasing how well a drug performs in comparison to placebo. He then expands on the power of AI in digital pathology and its ability to enhance assessment of biopsy beyond ordinal scoring systems. Jörn adds that these extension studies are fascinating for their ability to hone in on patient benefits experienced beyond liver histology alone. From here, the group discusses at length deepening the field's understanding of liver volume reduction.Moving on, Roger revisits a metaphor from Mazen Noureddin in last week's episode which likened the two most valuable properties in "NASH Monopoly" to GLP-1s and FGF-21s. Stephen suggests a takeaway to be that "GLP's are coming to the forefront as a very active player in the fields of obesity, diabetes and ultimately CV risk reduction." The group next agrees that, in Jörn's paraphrased words, while a defatting effect on the liver can be beneficial, treating obesity by itself does not outright resolve fibrogenic burden and there remains the need for more liver-directed drugs. Stephen expands on his recurring phrase of "not all FGF-21s are created equal" while transitioning the group's focus to consider the fact that an increasing number of patients are progressing to cirrhosis. The remainder of the conversation posits fascinating and far-reaching speculations on the future study of disease including revolutionizing the way we diagnose HCC. In final comments, each panelist touches on one additional element in the drug development landscape to emerge out of an exciting month of June. If you have questions or comments around the EASL Congress or ADA meetings, the discussed therapeutics, new nomenclature, or any other topic addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

In this episode, supported by Fortis Life Sciences, we delve into the relationship between mitochondria, inflammation and cancer, discussing the new techniques that are bearing fruit in this field, such as spatial analysis. Our expert insight for this episode comes from Phillip West, Principle Investigator of the West lab at Texas A&M Medicine (TX, USA). Philip explains the role mitochondria can play in cancer and heart disease, reveals some of his most exciting discoveries of late and provides technical tips for investigating this field. Listen on to discover how his use of spatial techniques has helped uncover mechanisms linking mitochondrial damage to the stifling of the immune system in the tumor microenvironment and the latest breakthroughs at the intersection of mitochondria and cancer. Contents: Introduction: 00:00-01:30The innate immune system, in inflammation and disease: 01:30-04:20The role of mitochondria in innate immunity: 04:20-07:00Categorizing DAMPS and their role in cardiovascular disease: 07:00-08:40Mitochondria and cancer: 08:40-11:55Techniques for the investigation of mitochondria: 11:55-15:20Best practice techniques for spatial studies: 15:20-17:35Discoveries made using spatial approaches to mitochondrial investigations: 17:35-19:55The latest developments in the intersection of mitochondria, cancer and inflammation: 19:55-22:20What is one thing you would ask for to improve your understanding of this field? 22:20-24:20

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Giselle Sholler, Director of the Isabella Santos Rare and Solid Tumor Program at the Levine Children's Hospital, and Professor of Pediatrics and Principle Investigator of the Sholler Pediatric Oncology Research Laboratory. Together they discuss trends in managing pediatric hematologic cancers and how molecular profiling and genomic profiling intersect with clinical care. For more information, please visit: www.CarisLifeSciences.com

We're all aware that street signs in Ireland are bilingual, but are these Irish names actually correct? In many cases, streets have two versions of an Irish name, one at either end. So how are we to know which name to use? Dr. Brian Ó Raghallaigh, Principle Investigator of the logainm project in DCU, joined us on the show to tell us more about the correct use of Irish place translations.

In this episode of HYDRATE, Tracy sits down with Prof. Roumiana Tsenkova, Founder of Aquaphotomics, Exploring Water Molecular System in Nature. Aquaphotomics is a new discipline introduced by Prof. Roumiana Tsenkova at Kobe University, Japan. It is a new “omics” discipline where the main object of this new field is to understand the role of the water molecular system in biological and aqueous systems. Prof. Roumiana's goal is to raise awareness among the general audience about aquaphotomics and the important role that water plays in life. She has written more than 23 chapters in books, 120 papers and 17 patent applications. She has been a Principle Investigator for more than 21 projects. Today, Prof. Roumiana talks about what is aquaphotomics, what got her into this field, why water is a living system, which water to drink, how to optimize your water body and so much more. Hope you find this episode valuable. Please feel free to share it with a friend or someone who may benefit from it. Enjoy the show!   Find Aquaphotomics on: Website: https://www.aquaphotomics.com/ Email: info@aquaphotomics.com   Check out Hallstein Water and use code HYDRATE to get 50% off of your first order. https://www.hallsteinwater.com/shop/us

Scientists came up with a method to produce concrete on the Moon and Mars using potato starch. In this interview, I'm talking with Dr Aled Roberts, who is the Principle Investigator of this research.

Scientists came up with a method to produce concrete on the Moon and Mars using potato starch. In this interview, I'm talking with Dr Aled Roberts, who is the Principle Investigator of this research.

Backed by decades of experience producing exceptional clinical outcomes, Kintinu Telerehab connects recovery to everyday life. In this podcast, we explore hot topics in rehabilitation, the keys to personal growth and recovery, and how to apply it all to the real-world.In this episode of Kintinu'd Conversations, Brad Dexter and Steve Kerschke continue their conversation with Tim Feeney.Dr. Tim Feeney consults on treatment of patients with acquired brain injury and specializes in neurobehavioral intervention. He is the Chief Knowledge Officer for Belvedere Health Services in Albany, NY and the Founder and Director of the Mill School in Burlington, VT. For 20 years Tim was the Project Director of the New York Neurobehavioral Resource Project, a CMS identified best practice model program developed to support individuals with brain injury and other neurogenic disorders and significant behavioral challenges to live successfully in their home communities. In addition he is a Principle Investigator for the Behaviours of Concern Project, a five year grant funded research project of Monash University in Melbourne, Australia. Tim has assisted numerous individuals and agencies in the development of system-wide changes in order to provide sustainable, high quality, and cost-effective education and rehabilitation services.Tim has been responsible for the procurement and coordination of over $15,000,000 in grant-funded programs serving individuals with challenging behaviors, autism, and persons with brain injury and challenging behaviors. Tim has authored over 75 scholarly journal articles and book chapters, is co-author, with Mark Ylvisaker, of the book Collaborative Brain Injury Intervention: Positive Everyday Routines, and travels the world over speaking to audiences about collaborative services designed to support individuals with complex needs. Enjoy!Listen to the episode on Spotify, Amazon Music, Apple Podcasts, and Buzzsprout, or on your favorite podcast platform.Listen to the episode on Spotify, Amazon Music, Apple Podcasts, and Buzzsprout, or on your favorite podcast platform.

Dr. Amber Gaffney is a social psychologist and the Principle Investigator of the Social Identity Lab. Her research focuses on social identity, group processes and social influence. She is also an Associate Professor of Social Psychology and Academic Research Graduate Program Coordinator for Cal Poly Humboldt. Stephanie Souter is the Co-Investigator of the Social Identity Lab and is an adjunct faculty member in the Department of Psychology at Cal Poly Humboldt. She is also a Research Analyst III in the office of Institutional Research, Analytics, and Reporting at Cal Poly Humboldt. You can find the Social Identity Lab online (@humboldtsilab.org).   0:00 | The Social Identity Lab and extremism in society   14:32 | Uncertainty and its relation to the group   23:19 | "Othering" people   29:41 | The effect of emotions on collective movements   35:49 | Prototypical vs non-prototypical leaders   47:31 | Group identity vs individual identity   1:00:32 | Well-defined groups vs ambiguous groups   1:09:55 | Social Identity Theory   1:23:22 | Research on the effect of self uncertainty on conspiracy theory adoption   1:30:09 | Nothing is true and everything is possible   1:35:22 | Research vs me-search

Backed by decades of experience producing exceptional clinical outcomes, Kintinu Telerehab connects recovery to everyday life. In this podcast, we explore hot topics in rehabilitation, the keys to personal growth and recovery, and how to apply it all to the real-world.In this episode of Kintinu'd Conversations, Brad Dexter and Steve Kerschke sit down to talk with Tim Feeney. Dr. Tim Feeney consults on treatment of patients with acquired brain injury and specializes in neurobehavioral intervention. He is the Chief Knowledge Officer for Belvedere Health Services in Albany, NY and the Founder and Director of the Mill School in Burlington, VT. For 20 years Tim was the Project Director of the New York Neurobehavioral Resource Project, a CMS identified best practice model program developed to support individuals with brain injury and other neurogenic disorders and significant behavioral challenges to live successfully in their home communities. In addition he is a Principle Investigator for the Behaviours of Concern Project, a five year grant funded research project of Monash University in Melbourne, Australia. Tim has assisted numerous individuals and agencies in the development of system-wide changes in order to provide sustainable, high quality, and cost-effective education and rehabilitation services.Tim has been responsible for the procurement and coordination of over $15,000,000 in grant-funded programs serving individuals with challenging behaviors, autism, and persons with brain injury and challenging behaviors. Tim has authored over 75 scholarly journal articles and book chapters, is co-author, with Mark Ylvisaker, of the book Collaborative Brain Injury Intervention: Positive Everyday Routines, and travels the world over speaking to audiences about collaborative services designed to support individuals with complex needs. Enjoy!Listen to the episode on Spotify, Amazon Music, Apple Podcasts, and Buzzsprout, or on your favorite podcast platform.Listen to the episode on Spotify, Amazon Music, Apple Podcasts, and Buzzsprout, or on your favorite podcast platform.

The prospect of day-to-day life with artificial intelligence is no longer a future endeavor. AI systems comprise countless applications across public and private organizations, and through open-sourced systems, such as ChatGPT, AI is now consumer-facing and usable. The U.S. National Institute of Standards and Technology was directed by the National Artificial Intelligence Initiative Act of 2020 to create a voluntary resource for organizations designing, developing, deploying or using AI systems to help manage risk and to promote trustworthy and responsible development of AI systems. As a result, NIST released the AI Risk Management Framework 1.0 along with supplementary documents to help organizations. To learn more about the newly released framework and how organizations should approach it, IAPP Editorial Director Jedidiah Bracy caught up with NIST Research Scientist and Principle Investigator for AI Bias Reva Schwartz.

Link from the show:* Connect with Matthew on Twitter* Connect with Ryan on Twitter* Subscribe to the newsletterAbout my guest:Dr. Matthew W. Johnson, Ph.D., is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world's most published scientists on the human effects of psychedelics, and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior. Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004.Working with psychedelics for 16 years, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. As Principle Investigator he developed and published the first research on psychedelic treatment of tobacco addiction in 2014. Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress in 2016. His 2018 psilocybin abuse liability review recommended placement in Schedule-IV upon potential medical approval. He is Principle Investigator on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. Beyond psilocybin, in 2011 Dr. Johnson published the first-ever blinded human research showing psychoactive effects of salvinorin A, the active constituent in Salvia divinorum. He also published in 2017 the first data indicating that MDMA pill testing services may reduce harm, specifically by reducing drug consumption of unknown or undesired adulterants.Dr. Johnson is recognized for his research in behavioral economics, behavioral pharmacology, and behavior analysis. He has conducted seminal and widely cited research applying behavioral economic principles such as delay discounting and demand analysis to decision making within addiction, drug consumption, and risk behavior. This includes research determining delay discounting to be a fundamental behavioral process underlying addiction across drug classes, using economic demand analysis to determine the roles of nicotine and nonpharmacological factors in the abuse liability tobacco and other nicotine products, and using delay discounting, probability discounting, and demand analysis to understand sexual risk including condom non-use in casual sex situations. He conducted the first research administering cocaine to humans in determining that cocaine increases sexual desire and affects sexual decision making. He has conducted similar research administering methamphetamine and alcohol, examining effects on sexual decision making. He has published studies on drugs across nearly all psychoactive classes, including studies of cocaine, methamphetamine, tobacco/nicotine, alcohol, opioids, cannabis, benzodiazepines, psilocybin, dextromethorphan, salvinorin A, GHB, caffeine, and cathinone analogs compounds (so-called “bath salts”).Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for >75 journals and has served as guest editor on two special issues on psychedelics. Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.Dr. Johnson has been interviewed widely by media about psychedelics and other drugs. These have included interviews by the New York Times, the Washington Post, the Wall Street Journal, the Globe and Mail, the Daily Mail, USA Today, the Chicago Tribune, the San Francisco Chronicle, the Denver Post, the Baltimore Sun, CNN, CBS News, NBC News, the Atlantic, Newsweek, Vanity Fair, Marie Claire, Vogue, Whole Living, the Washingtonian, Scientific American, Nature, Vice, Insider, Inverse, Healthline, and Psychology Today. Dr. Johnson has appeared for interviews on numerous television and radio shows including 60 Minutes, CNN's Wolf Blitzer Situation Room, Fox Business News' Kennedy, the Dr. Oz Show, PBS' Retro Report, Labyrint (television show in the Netherlands), Spectrum News NY1, the BBC World Service, NPR's Morning Edition, NPR's Kojo Nnamdi Show, New Zealand Radio, and Newstalk Radio Ireland. Dr. Johnson's panel discussion with Tim Ferriss at the Milken Institute Global Conference was broadcast on the Tim Ferriss Podcast. Dr. Johnson and his research were featured in an episode of Breakthrough on the National Geographic Channel, produced by Ron Howard, and in Michael Pollan's best-selling book, How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Get full access to Dispatches from the War Room at dispatchesfromthewarroom.substack.com/subscribe

The OPTIMA trial took place at 7 locations in 4 provinces across Canada and evaluated two opioid agonist treatment models of care:Methadone and Buprenorphine/Naloxone (Suboxone).When the idea for OPTIMA began, Methadone was the standard of care for people who used opioids.Suboxone was also available but not as frequently prescribed.Physicians wanted to be able to provide Suboxone based on the needs of the client and wanted to be able to do this without having the patient come into the pharmacy all the time to get itThey called it “flexible take-home dosing”Join us this week for a conversation with Principle Investigator, Didier Jutras-Aswad with the CRCHUM Research Centre in Montreal, Quebec, to learn about what they found, and our opinion on how these findings may affect people who are on Opioid Agonist Therapy.You won't want to miss this one friends, as we push to the front line of research on this special live edition,of Hard Knox Talks.Buckle up! Love what we do? Stay up to date on upcoming live streams, get on our email list, check out our shop, listen to our audios, and more. Click the link to start exploring.https://linktr.ee/hardknoxtalks

David Stewart, MD; Head, Division of Medical Oncology, University of Ottawa; Author, A Short Primer on Why Cancer Still SucksDr. Stewart received his MD degree from Queen's University, Kingston, followed by training in internal medicine at McGill University and in medical oncology in the Department of Developmental Therapeutics at the UT MD Anderson Cancer Center. He first moved from MD Anderson to the University of Ottawa in 1980, and served as Chief of Medical Oncology at the Ottawa Civic Hospital from 1989 to 1999. He returned to the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center from 2003 to 2011 where he served as Chief of the Section of Experimental Therapeutics (2003-2005), Chair Ad Interim (2005), Deputy Chair (2006-2009), and Director of Translational Research (2009-2011). He was also the Principle Investigator of MD Anderson' phase II N01 contract with the National Cancer Institute, and was the clinical leader of a number of other federally-funded translational research projects. In 2011, Dr. Stewart returned to Ottawa from the University of Texas MD Anderson Cancer Center (Houston, TX) in 2011 to assume the position of Head of the Division of Medical Oncology at The Ottawa Hospital and the University of Ottawa. John Marchica, CEO, Darwin Research GroupJohn Marchica is a veteran health care strategist and CEO of Darwin Research Group. He is leading ongoing, in-depth research initiatives on integrated health systems, accountable care organizations, and value-based care models. He is a faculty associate in the W.P. Carey School of Business and the graduate College of Health Solutions at Arizona State University.John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is an active member of the American College of Healthcare Executives and is pursuing certification as a Fellow. About Darwin Research GroupDarwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin's client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Today, our guest is Dr. Mikeal Parsons, Professor and Macon Chair in Religion at Baylor University. Dr. Parsons is a New Testament Scholar specializing in the Gospels and the book of Acts through the lens of rhetoric and literary criticism. Author or editor of over 30 books, Dr. Parsons has served as co-director of a Wabash grant for graduate student teaching. More recently, Dr. Parsons is a co-Principle Investigator on another Wabash-funded teaching project focusing on Pedagogical Practices and Faith traditions. We are delighted to have Dr. Parsons on the show to discuss graduate student training in teaching, the implications of religious backgrounds for teaching, and much more.

Les Johnson is the Principle Investigator with NASA's upcoming Near-Earth Asteroid Scout mission that will fly on the SLS and test solar sail navigation. But at the same time, he's a science fiction author. So, in this interview, we discussed both these sides of his life.

Les Johnson is the Principle Investigator with NASA's upcoming Near-Earth Asteroid Scout mission that will fly on the SLS and test solar sail navigation. But at the same time, he's a science fiction author. So, in this interview, we discussed both these sides of his life.

Ivy Baremore works as the Technical Coordinator for MarAlliance as well as the Principle Investigator for deep water fisheries. Kristen talks to Ivy about her work accessing populations of large fish living on the reef as well as her work looking into the world of deep water fish. They also have a discussion about refinding the Atlantic Sixgill Shark in Belize and how data management hooked Ivy into the world of science. Enjoy! Follow Ivy: On Twitter Follow MarAlliance: On Instagram On Twitter On Facebook Follow Gills Club: On Instagram On Twitter On Facebook --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/gillstalk/support

Gene therapy! The next big thing. But what does it all mean? What are the ethics? Where did it even come from? What in the sweet hell is CRISPR? This week we hop in the time travel machine and head all the way back to that time the fellas are joined by Dr. Graham Dellaire, Professor of Pathology at Dal & Principle Investigator at the Dellaire Lab of Nuclear Structure and Cancer Biology. He drops some fascinating knowledge on all things gene therapy & gene editing! This episode is a nerd's wet dream. Sickboy LIVE in Edmonton Tickets: https://www.eventbrite.ca/e/sickboy-live-in-edmonton-tickets-400700244217 Sickboy LIVE in Vancouver Tickets: https://admitone.com/events/sickboy-podcast-vancouver-8301026 Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

3500 TEENS ・ 2 RESEARCHERS ・ 1 QUESTION What are adults missing about teens and technology? A lot. Drawing on perspectives from more than 3,500 teens, Harvard Project Zero researchers Emily Weinstein and Carrie James bring stories and data together for a powerful reframe of what teens are up against – and what teens need adults to understand. Emily Weinstein is a Research Director at Project Zero at Harvard and a Lecturer at the Graduate School of Education. Carrie James is a sociologist and Principle Investigator at Project Zero at the Harvard Graduate School of Education. She is the author of Disconnected: Youth, New Media, and the Ethics Gap (MIT Press). The authors' work has been covered in Time, the Boston Globe, the Washington Post, and the Atlantic, and they are sought-after speakers on teens and technology. You can learn more at www.behindtheirscreens.com       Learn more about your ad choices. Visit megaphone.fm/adchoices

Today for our Explorers Club series, we are about to be hit by a meteorite of space knowledge as we have a wildly accomplished scientist and researcher entering our atmosphere, Dr. Nina Lanza. She is the Team Lead for Space and Planetary Exploration in Space and Remote Sensing at Los Alamos National Laboratory. She is also the Principle Investigator of the ChemCam instrument on the Mars Curiosity Rover (sadly not sponsored by us) and a team member for the SuperCam instrument on the Mars Perseverance rover. She's an expert on Mars and does a lot of research on meteorites and minerals that can tell us about the interactions between rocks, soil, atmosphere, and water on the planet.Nina Lanza Interview from 4/23/22Dr. Nina Lanza - About Ninahttps://www.ninalanza.com/about-nina/NASA's Curiosity Rover Measures Intriguing Carbon Signature on Marshttps://mars.nasa.gov/news/9113/nasas-curiosity-rover-measures-intriguing-carbon-signature-on-mars/?site=msl2020 Mission Perseverance Rover - SuperCamhttps://mars.nasa.gov/mars2020/spacecraft/instruments/supercam/Mount Sinai - Manganesehttps://www.mountsinai.org/health-library/supplement/manganese#:~:text=Manganese%20is%20a%20trace%20mineral,clotting%20factors%2C%20and%20sex%20hormones.Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/explorers-club-nina-lanza

I'm offering 40% off for a 4-pack of one on one coaching sessions for the month of May. To inquire more go to www.nicobarraza.comThis week's guess is Dr. Lisa Miller. An NYT Bestselling Author.Dr. Lisa Miller is perhaps the world's foremost expert in the relative study of psychology and spirituality. Dr. Miller is Professor and Director of Clinical Psychology at Teachers College, Columbia University, where she founded and currently directs the Spirituality and Mind-Body Institute, to innovate, disseminate, and train healers in foundationally spiritual treatments. Dr. Miller solo-edited the Oxford University Handbook of Psychology and Spirituality (2012) and has published over seventy articles and chapters on spirituality in mental health and wellness. She has acted as Principle Investigator on several million dollars-worth of grants from corporate and family foundations as well as the National Institutes of Mental Health.You can purchase Dr. Miller's books (The Awakened Brain) & (The Spiritual Child)  and find out more about her research and work here https://www.lisamillerphd.com/Her TedTalk on Depression and Spirituality can be found here https://www.youtube.com/watch?v=7c5t6FkvUG0Connect with her on Instagram at @Dr.LisaMiller